The company DLD Gesellschaft für Diagnostika und medizinische Geräte mbH was founded in February 1994. The two owners and managing directors are Dr. Matthias Deparade and Dr. Rolf Lehmann.
DLD develops, markets and provides scientific service for high quality innovative tests for in vitro diagnosis, especially for autoimmune diseases, cardiovascular diseases, cancer diseases and renal dysfunction.
The methodology of the tests is chiefly based on immunoassay techniques such as Radioimmunoassays (RIA) and Enzyme immunoassays (ELISA).
DLD stands for innovative products and high level research and development in cooperation with several study groups.
DLD is the coordinating point between research and routine lab.